United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, Argus Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price target increased by analysts at Argus from $360.00 to $400.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Argus’ price target would suggest a potential upside of 6.95% from the stock’s current price.

Other equities analysts have also issued reports about the company. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Jefferies Financial Group lifted their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Trading Up 0.0 %

Shares of UTHR stock opened at $374.02 on Thursday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $16.64 billion, a PE ratio of 16.43, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57. The firm has a 50 day moving average price of $355.40 and a two-hundred day moving average price of $316.65. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $377.92.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the firm earned $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, analysts predict that United Therapeutics will post 24.75 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares in the company, valued at $2,442,300. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 7,800 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,412 shares of company stock valued at $33,971,508 over the last 90 days. Insiders own 11.90% of the company’s stock.

Institutional Trading of United Therapeutics

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its stake in United Therapeutics by 85.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock valued at $594,000 after purchasing an additional 1,191 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in United Therapeutics by 1.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 184,934 shares of the biotechnology company’s stock valued at $42,483,000 after acquiring an additional 3,537 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of United Therapeutics by 2.5% during the first quarter. State of Michigan Retirement System now owns 12,232 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 300 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of United Therapeutics by 0.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company’s stock worth $23,211,000 after purchasing an additional 338 shares during the period. Finally, State of Alaska Department of Revenue increased its position in United Therapeutics by 153.5% in the first quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock worth $3,802,000 after buying an additional 10,025 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.